Join
Acumen Research
@acumenresearchmarket2019
Market Research Report
January 10, 2020

Hepatitis B Vaccine Market Size is Expected to Grow at 5.8% CAGR By 2027

Hepatitis B Vaccine Market (By Type: Single Antigen Hepatitis B Vaccine, Combination Vaccines; By Dose: 3-Dose Schedule, 2-Dose Schedule, Alternate Schedule; By End User: Hospitals, Clinics, Doctor Offices, Others) – Global Industry Analysis, Market Size, Opportunities And Forecast, 2019 - 2027

A report by Acumen Research and Consulting estimated that the Hepatitis B Vaccine Market will surpass $2,136.7 million by 2027, representing an average annual growth rate of 5.8 percent from 2019 to 2027.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1661

In 2018, North America held the major share of the global market for the Hepatitis B vaccine and the region is also anticipated to maintain its dominance during the forecast period from 2019 to 2026. The region is primarily gaining growth owing to the increasing number of cases affected by the Hepatitis B virus. The region is also having potential share due to its advanced healthcare infrastructure. According to the American Academy of Family Physicians (AAFP), around 1.25 million Americans had chronic hepatitis B in the year 2004 and according to the WHO 2019 estimates for America region, 0.7% of the population is infected with the Hepatitis B virus.

The combination vaccines segment accounted for the major share by type in the hepatitis B vaccine market due to its characteristics of protection against multiple causative agents. The combination vaccine also decreases the cost of packaging, which is administered for individual vaccines and is also contributing to the segment market growth. For instance, a combination vaccine name Twinrix can protect against both hepatitis B and hepatitis A. Some of the other combination vaccines names include Ambirix, Comvax, and Hexacima/ Hexyon.

On the basis of dose, the 3-Dose Schedule segment is dominating the market with a major share. The segment is particularly gaining positive growth because it is prominently recommended for the infants due to the high risk of the virus which can develop a lifelong infection if they are exposed to the hepatitis B virus. Furthermore, VBI Vaccines Inc. announced the company’s abstract based on the 3-Dose hepatitis B (HepB) vaccine, which is selected for a late-breaker oral presentation at IDWeek 2019, in Washington, D.C. Moreover, 2-dose schedule hepatitis B vaccine is projected to be the fastest growing segment over the estimated period. HEPLISAV-B is the first and only 2-dose hepatitis B vaccine offered by Dynavax Technologies Corporation is approved by U.S. Food and Drug Administration (FDA).

Hospitals segment by end-user exhibited maximum growth in the year 2018 and the segment is also anticipated to continue with the same pace over the forecast period 2019 to 2026. The segment is having potential share owing to the large volume of product sales in the hospitals. The first dose of the Hepatitis B vaccine is recommended to be administered before the discharge of infants from the hospitals, which is supporting the segment growth.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/hepatitis-b-vaccine-market

Related Reports

  • Vaccines Market - The global market is expected to grow at a CAGR of around 6.4% from forecast period 2019 to 2026 and to reach the market value of around US$ 55.2 billion by 2026.
  • Meningococcal Vaccines Market - The global market value is estimated to hit USD 9.37 billion by 2026 and expected to grow at a CAGR of 12.3% over period 2019 to 2026.
  • Biopharmaceutical CMO & CRO Market - The global market is expected to grow at noteworthy CAGR around 7.5 % throughout the forecast period and reach around US$ 39 billion by 2026.

Some of the leading competitors are Sanofi, Merck & Co., Inc., GlaxoSmithKline plc, Indian Immunologicals Limited, LG Chem, KM Biologics, Dynavax Technologies, and Janssen Pharmaceuticals. Hepatitis B Vaccine companies have announced mergers and acquisitions to expand their position in the Hepatitis B Vaccine industry. Major players are also moving into new regions with advanced technologies to treat hepatitis B virus-infected people better.

Some of the key observations regarding Hepatitis B Vaccine industry include:

  • The U.S. Food and Drug Administration has approved VAXELIS, a diphtheria, and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus B conjugate, and hepatitis B vaccine particularly for children from 6 weeks to 4 years of age.
  • Sanofi and Merck have developed VAXELIS as part of a joint-partnership. The companies are working to maximize the production of VAXELIS to meet expected demand in the U.S. market. The companies are additionally working to fill the supply and demand gap till 2020.
  • LG Chem. will receive US$33.4 million (37 billion won) from the Bill & Melinda Gates Foundation for the development of a six-in-one vaccine. LG Chem’s six-in-one vaccine that prevents six diseases with high mortality rates in infants, including diphtheria, tetanus, pertussis, hepatitis B, meningitis, and poliomyelitis.
  • In 2017, Dynavax Technologies Corporation announced that the U.S. Food and Drug Administration (FDA) have approved HEPLISAV-B for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
  • In 2018, The Janssen Pharmaceutical Companies of Johnson & Johnson entered into an agreement with Arrowhead Pharmaceuticals, Inc., for an exclusive, worldwide license to develop and commercialize ARO-HBV, a Phase 1/2 subcutaneous, RNAi therapy candidate being investigated for the treatment of chronic HBV infection.

Market Segmentation

Market By Type

  • Single Antigen Hepatitis B Vaccine
  • Combination Vaccines

Market By Dose

  • 3-Dose Schedule
  • 2-Dose Schedule
  • Alternate Schedule

Market By End User

  • Hospitals
  • Clinics
  • Doctor Offices
  • Others (Medical Camp, Local Health Department)

Market By Geography


  • North America
    U.S.
    Canada


  • Europe
    UK
    Germany
    France
    Spain
    Rest of Europe


  • Asia-Pacific
    China
    Japan
    India
    Australia
    South Korea
    Rest of Asia-Pacific


  • Latin America
    Brazil
    Mexico
    Rest of Latin America


  • Middle East & Africa
    GCC
    South Africa
    Rest of Middle East & Africa

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Hepatitis B Vaccine
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Hepatitis B Vaccine Market By Type
1.2.2.1. Global Hepatitis B Vaccine Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Hepatitis B Vaccine Market Revenue Share By Type in 2018
1.2.2.3. Single Antigen Hepatitis B Vaccine
1.2.2.4. Combination Vaccines
1.2.3. Hepatitis B Vaccine Market By Dose
1.2.3.1. Global Hepatitis B Vaccine Market Revenue and Growth Rate Comparison By Dose (2015-2026)
1.2.3.1.1. 3-Dose Schedule
1.2.3.1.2. 2-Dose Schedule
1.2.3.1.3. Alternate Schedule
1.2.4. Hepatitis B Vaccine Market By End User
1.2.4.1. Global Hepatitis B Vaccine Market Revenue and Growth Rate Comparison By End User (2015-2026)
1.2.4.2. Hospitals
1.2.4.3. Clinics
1.2.4.4. Doctor Offices
1.2.4.5. Others
1.2.5. Hepatitis B Vaccine Market By Geography
1.2.5.1. Global Hepatitis B Vaccine Market Revenue and Growth Rate Comparison By Geography (2015-2026)
1.2.5.2. North America Hepatitis B Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Hepatitis B Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Hepatitis B Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Hepatitis B Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Hepatitis B Vaccine Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Hepatitis B Vaccine Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Hepatitis B Vaccine Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Hepatitis B Vaccine Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Hepatitis B Vaccine Major Manufacturers in 2018

CHAPTER 4. HEPATITIS B VACCINE MARKET BY TYPE
4.1. Global Hepatitis B Vaccine Revenue By Type
4.2. Single Antigen Hepatitis B Vaccine
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Combination Vaccines
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. HEPATITIS B VACCINE MARKET BY DOSE
5.1. Global Hepatitis B Vaccine Revenue By Dose
5.2. 3-Dose Schedule
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. 2-Dose Schedule
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Alternate Schedule
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. HEPATITIS B VACCINE MARKET BY END USER
6.1. Global Hepatitis B Vaccine Revenue By End User
6.2. Hospitals
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Clinics
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Doctor Offices
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA HEPATITIS B VACCINE MARKET BY COUNTRY
7.1. North America Hepatitis B Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Hepatitis B Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Hepatitis B Vaccine Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE HEPATITIS B VACCINE MARKET BY COUNTRY
8.1. Europe Hepatitis B Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Hepatitis B Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC HEPATITIS B VACCINE MARKET BY COUNTRY
9.1. Asia-Pacific Hepatitis B Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Hepatitis B Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA HEPATITIS B VACCINE MARKET BY COUNTRY
10.1. Latin America Hepatitis B Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Hepatitis B Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
10.4. Mexico
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST & AFRICA HEPATITIS B VACCINE MARKET BY COUNTRY
11.1. Middle East & AFRICA Hepatitis B Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East & AFRICA Hepatitis B Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
11.4. South Africa
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
11.5. Rest of Middle East & AFRICA
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Dose, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE
12.1. Sanofi
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Type Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Merck & Co., Inc.
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Type Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. GlaxoSmithKline plc.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Type Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Indian Immunologicals Limited.
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Type Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. LG Chem
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Type Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. KM Biologics
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Type Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Dynavax Technologies
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Type Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Janssen Pharmaceuticals
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Type Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Others
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Type Portfolio
12.9.5. Key Developments
12.9.6. Strategies

CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1661

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.


Acumen Research
January 10, 2020, 10:05
0 views
0 reactions